Skip to main content

Table 1 Demographics of 92 patients with Candida auris

From: Clinical spectrum and factors impacting outcome of Candida auris: a single center study from Pakistan

Category Total n = 92 (100%)
Male 48 (52.2%)
Age group
 16–35 years 20 (21.7%)
 36–55 years 26 (28.3%)
 56–75 years 30 (32.6%)
 76–96 years 16 (17.4%)
Location in hospital
 ICU 30 (32.6%)
 Special care 30 (32.6%)
 Ward 27 (29.3%)
 Outpatient 5 (5.4%)
Diabetes mellitus 26 (28.3%)
 Malignancy 17 (18.5%)
 Surgery 53 (57.6%)
  Abdominal 12 (13%)
  Cardiothoracic 8 (8.7%)
  Neurosurgery 14 (15.2%)
  ENT 9 (9.8%)
  Orthopedics 7 (7.6%)
  Others 2 (2.17%)
 ICU stay in last 30 days 41 (44.6%)
 Last ICU stay duration (weeks) ≤ 2 Weeks 31 (75.6%)
 HDU stay in last 30 days 62 (67.4%)
Last HDU stay duration (weeks)
  ≤ 2 Weeks 52 (56.5%)
 Indwelling lines 81 (88.04%)
 Antibiotics in last 90 days 88 (95.6%)
 Antifungals in last 90 days 36 (39.1%)
 Fluconazole 19 (20.7%)
 Voriconazole 3 (3.3%)
 Amphotericin 7 (7.6%)
 > 1 Antifungal 7 (7.6%)
Prior antifungal duration (weeks)
  ≤ 2 Weeks 25 (27.2%)
Isolation of multi-drug resistant bacteria
 Prior toC.auris (≤ 90 days) 48 (52.2%)
 Coinfection with C.auris 29 (31.5%)
 Infected cases 65 (70.7%)
 Candidemia 38 (58.5%)
 Non-candidemia 27 (41.5%)
  UTI 19
  Peritonitis 3
  Nosocomial ventriculitis 1
  Empyema 1
  Surgical Site Infection 1
  Otitis externa 1
  Keratitis 1
Colonized cases 27 (29.3%)
 Asymptomatic candiduria 21
 Central line tip 4
 Ear Swab 1
 Oral Swab 1
Antifungal resistance (n = 63)
 Fluconazole 63 (100%)
 Voriconazole 18 (28.57%)
 Amphotericin 5 (7.93%)
Mean hospital stay (days) 30.73
Median hospital stay (days) 25 (1–163)
Mortality 39 (42.4%)
C auris death 19 (48.7%)
14-day mortality 29 (31.5%)
Mean days in which mortality occurred (days) 12.41
Median days in which mortality occurred (days) 7 (1–69)
Clinical failure 38 (41.3%)
Microbiological failure (Candidemia) 11 (40.74%)